Yahoo Finance

Vector Science & Therapeutics Announces Landmark Exclusive cGMP Manufacturing Agreement with LyoGenesis Plus for Its Proprietary Peptide Portfolio

MEQUON, Wis., July 7, 2026 /PRNewswire/ -- Vector Science & Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") today announced an exclusive licensing and manufacturing agreement with ...

Vector Sciences & Therapeutics: Vector Science & Therapeutics Corp., LyoGenesis Plus and Wynn Pharmaceuticals Announce Strategic Collaboration to Develop and Manufacture ...

LyoGenesis Plus 1, LLC ("LyoGenesis Plus"), a company related to Vector Science & Therapeutics Corp. ("Vector") ...

Vector Sciences & Therapeutics: Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28

Peptide manufacturing vertical on track to begin generating revenue in August 2026; VectorMist 510(k) submission advancing toward FDA filing MEQUON, Wis., July 24 ...
Morningstar

Vector Science & Therapeutics Names Dexter Fowler as Chief Athletic Officer for Its Valor Platform

14-Year MLB Veteran and 2016 World Series Champion Joins Valor, Vector's Athlete Platform, to Make Sure the Next Generation Plays Longer and Hurts Less MEQUON, Wis., June 12, 2026 /PRNewswire/ -- ...

Vector Science & Therapeutics Corp., LyoGenesis Plus and Wynn Pharmaceuticals Announce Strategic Collaboration to Develop and Manufacture Critical Care Medical Products

LyoGenesis Plus 1, LLC ("LyoGenesis Plus"), a company related to Vector Science & Therapeutics Corp. ("Vector"), and Wynn Pharmaceuticals LLC ("Wynn") today announced they have entered into a ...